Loading
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Previous close
$74.67
+$0.34 · +0.46%
Regular session · ET · Market data may be delayed.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Day range
Current $74.67
52-week range
Current $74.67
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
42
Fair Value
Sentiment
53
Mixed
Risk
32
Moderate Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Day range
Current $74.67
52-week range
Current $74.67
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.04M USD | 1.14M USD | 204K USD | 191K USD | 10.36M USD |
| Cost of goods sold | 4.65M USD | 82.1M USD | 45.75M USD | 15K USD | 10K USD |
| Gross profit | −607K USD | −80.96M USD | −45.55M USD | 176K USD | 10.35M USD |
| Research and development | 116.64M USD | 82.1M USD | 45.75M USD | 29.03M USD | 18.32M USD |
| Selling, general, and administrative | 73.53M USD | 33.7M USD | 9.9M USD | 6.39M USD | 4.64M USD |
| Operating expenses | 190.17M USD | 33.7M USD | 9.9M USD | 35.42M USD | 22.95M USD |
| Interest income | 29.93M USD | 26.62M USD | 6.9M USD | — | — |
| Interest expense | — | — | — | 1K USD | 451K USD |
| Depreciation and amortization | 1.45M USD | 32K USD | 17K USD | 15K USD | 10K USD |
| Operating income | −190.77M USD | −114.67M USD | −55.45M USD | −35.25M USD | −12.61M USD |
| Net income | −161M USD | −88.04M USD | −48.61M USD | −35.44M USD | −12.84M USD |
Company facts updated Sep 7, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI170.29M0.01%2.3T USD0.03%$379.73-0.32%
State Street SPDR S&P Biotech ETFXBI143.33M1.25%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 ETFIWM140.6M0.18%79.88B USD0.19%$296.01+0.28%
Vanguard Morningstar Small-Cap ETFVB122.73M0.07%183.4B USD0.03%$300.01+0.05%
Vanguard Extended Market ETFVXF61.46M0.06%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO51M0.35%14.58B USD0.24%$377.54+0.12%
Vanguard Morningstar Small-Cap Value ETFVBR38.97M0.06%68.3B USD0.05%$247.11+0.08%
Vanguard Morningstar Small-Cap Growth ETFVBK35.42M0.08%43.8B USD0.05%$349.44+0.01%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Morningstar Small-Cap Value ETFVBRVanguard Morningstar Small-Cap Growth ETFVBKAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
